Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

QuidelOrtho Corp

QDEL Nasdaq In Vitro & In Vivo Diagnostic Substances Financials FY2020–FY2025

Last close · Oct 23, 2026

$13.73

1.9%
Compare
Revenue Total sales reported in the income statement.
$2.7B
1.9% vs prior year
Operating margin Operating income as a share of revenue.
−33.7%
36.8 pts
Net income Profit after all expenses, interest and tax.
−$1.1B
Free cash flow Cash from operations minus capital spending.
−$83.0M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
−15.7%
11.4 pts
Market cap Last close times the latest diluted share count, so it is approximate.
$938M
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
—
On −$15.44 EPS (TTM)

What QuidelOrtho Corp does

No business description yet.

Legal name
QuidelOrtho Corp
Fiscal year ends
December 28, 2025
Latest annual report
10-K · Feb 19, 2026
Accession · CIK
0001906324-26-000008
0001906324

Revenue and margins

QuidelOrtho Corp had $2.7B of revenue in fiscal 2025, down 1.9% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was −$83.0M in fiscal 2025, −3.0% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

QuidelOrtho Corp returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 0.9%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably QuidelOrtho Corp can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $829M$345M$167M$98.3M$170M
Debt incl. finance leases $1.3M$2.9B$2.6B$2.8B$2.9B
Net debt / EBITDA −0.9x2.2x4.0x——
Debt / equity 0.0x0.6x0.5x0.9x1.5x
Interest coverage —11.1x0.9x−12.0x−5.2x
Current ratio 4.5x1.6x1.6x1.2x1.5x
Quick ratio 3.8x1.0x0.9x0.7x0.9x
Total assets $2.4B$8.9B$8.6B$6.4B$5.8B
Total liabilities $501M$3.9B$3.6B$3.4B$3.8B
Shareholders' equity $1.9B$4.9B$5.0B$3.0B$1.9B
Net debt (− = net cash) −$827M$2.5B$2.4B$2.7B$2.7B

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY20FY21FY22FY23FY24FY25
Net income is positive ✓ ✓ ✓ ✕ ✕ ✕
Cash from operations is positive ✓ ✓ ✓ ✓ ✓ ✓
Return on assets rose — — ✕ ✕ ✕ ✓
Cash from operations exceeds net income ✕ ✓ ✓ ✓ ✓ ✓
Debt fell relative to assets — — ✕ ✓ ✕ ✕
Current ratio rose — — ✕ ✓ ✕ ✓
Share count didn't rise — ✓ ✕ ✕ ✕ ✕
Gross margin rose — — — — — —
Revenue rose relative to assets — — ✕ ✕ ✓ ✓
F-score — / 3— / 43 / 84 / 83 / 85 / 8
Accruals ratio —−4.2%−6.0%−3.3%−28.5%−20.3%
Altman Z'' —11.783.192.78−0.85−0.56

6 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

Download CSV
Fiscal yearFY20FY21FY22FY23FY24FY25
Income statement
Revenue $1.7B $1.7B $3.3B $3.0B $2.8B $2.7B
Net interest income −$8.5M −$5.8M −$75.7M −$148M −$164M —
Research and development $84.3M $95.7M $188M $245M $219M $186M
Operating income $1.1B $906M $844M $139M −$2.0B −$919M
Interest expense — — $75.7M $148M $164M $178M
Pretax income $1.0B $900M $736M −$29.1M −$2.1B −$1.1B
Income tax $230M $196M $187M −$19.0M −$79.5M $24.1M
Net income $810M $704M $549M −$10.1M −$2.1B −$1.1B
Diluted EPS $18.60 $16.43 $9.56 −$0.15 −$30.54 −$16.69
Diluted shares 0.04B 0.04B 0.06B 0.07B 0.07B 0.07B
Cash flow
Cash from operations $630M $806M $885M $280M $83.0M $105M
Capital expenditure $64.9M $293M $141M $209M $195M $188M
Free cash flow $565M $513M $744M $70.9M −$112M −$83.0M
Depreciation and amortization $48.8M $52.7M $284M $457M $453M $442M
Stock-based compensation $21.0M $25.4M $48.4M $51.6M $42.1M $45.9M
Acquisitions $0.0M $0.0M $1.5B $0.0M $0.0M —
Share buybacks $43.7M $104M $74.3M $7.2M $0.0M $0.0M
Dividends and buybacks $43.7M $104M $74.3M $7.2M $0.0M $0.0M
Balance sheet
Cash and short-term investments $490M $829M $345M $167M $98.3M $170M
Total debt — $1.3M $2.9B $2.6B $2.8B $2.9B
Finance lease liabilities — — — $0.4M $7.9M $1.6M
Current assets — $1.4B $1.6B $1.3B $1.2B $1.4B
Current liabilities — $324M $1.0B $834M $999M $966M
Inventory — $199M $524M $578M $534M $578M
Property and equipment, net — $349M $1.3B $1.4B — —
Goodwill — $337M $2.5B $2.5B $650M $0.0M
Intangible assets — $98.7M $3.1B $2.9B $2.7B $2.6B
Total assets — $2.4B $8.9B $8.6B $6.4B $5.8B
Total liabilities — $501M $3.9B $3.6B $3.4B $3.8B
Preferred stock — $0.0M $0.0M $0.0M $0.0M $0.0M
Shareholders' equity $1.3B $1.9B $4.9B $5.0B $3.0B $1.9B
Margins
Operating margin 63.8% 53.3% 25.8% 4.6% −70.5% −33.7%
EBITDA margin 66.7% 56.4% 34.5% 19.9% −54.2% −17.5%
Net margin 48.8% 41.5% 16.8% −0.3% −73.7% −41.5%
FCF margin 34.0% 30.2% 22.8% 2.4% −4.0% −3.0%
Net interest share of revenue −0.5% −0.3% −2.3% −4.9% −5.9% —
Returns
Return on capital — 64.3% 8.4% 1.5% −27.1% −15.7%
Return on capital employed — 43.0% 10.7% 1.8% −36.1% −19.1%
Return on equity 60.8% 43.2% 16.0% −0.2% −51.4% −46.1%
Return on assets — 29.0% 9.7% −0.1% −27.4% −18.6%
Return on tangible equity 60.8% 47.1% — — — —
Growth
Revenue growth — 2.2% 92.3% −8.2% −7.2% −1.9%
Net income growth — −13.1% −22.1% −101.8% — —
EPS growth — −11.7% −41.8% −101.6% — —
FCF growth — −9.2% 45.1% −90.5% −258.1% —
Share count change — −1.6% 33.8% 16.4% 0.6% 0.9%
Financial health
Net debt / EBITDA — −0.9x 2.2x 4.0x — —
Debt / equity — 0.0x 0.6x 0.5x 0.9x 1.5x
Interest coverage — — 11.1x 0.9x −12.0x −5.2x
Current ratio — 4.5x 1.6x 1.6x 1.2x 1.5x
Quick ratio — 3.8x 1.0x 0.9x 0.7x 0.9x
Capital allocation
Capex / revenue 3.9% 17.2% 4.3% 7.0% 7.0% 6.9%
Stock comp / revenue 1.3% 1.5% 1.5% 1.7% 1.5% 1.7%
Payouts / FCF 7.7% 20.2% 10.0% 10.2% — —
Quality scores
Piotroski F-score — — 3.0 4.0 3.0 5.0
Altman Z'' — 11.8 3.2 2.8 −0.8 −0.6
Accruals ratio — −4.2% −6.0% −3.3% −28.5% −20.3%

Source: SEC EDGAR XBRL filings (CIK 0001906324). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open